If Brilacidin is developed into an inhaler/nebulizer form
If Brilacidin is developed into an inhaler/nebulizer form after it has shown great efficacy and safety as an IV for CV19, would that delivery system be automatically made available to patients or would those systems have to go thru a safety test of their own?
I see this as the great ending to the current lockdowns / mask wearing / non-traveling conditions affecting the world today.
I also wonder if that system would also be able to replace flu shots, not to mention other coronavirus conditions once sufficient testing has been done for other coronavirus conditions.
Looking forward to the first half of 2021 for IPIX on many fronts.
6
1
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Understanding NextPlat's Recent E-Commerce Adjustments NextPlat Corp (NASDAQ: NXPL), a global leader in e-commerce solutions, has announced critical changes to its operations as a response to the evolving trade landscape between the United States and China. The company anticipates that the recently imposed tariffs will significantly affect its ability to sell...
Continue Reading
Join the Exciting JiggAerobics Event for a Healthier You Northeast Delta Human Services Authority (NEDHSA) is thrilled to announce its upcoming JiggAerobics event, now in its seventh installment. This lively gathering aims to promote health and fitness among people of all ages, offering a blend of fun and physical activity. Details of the Event The JiggAerobics event is...
Continue Reading
VanEck UCITS ETFs plc: Comprehensive Prospectus Overview VanEck UCITS ETFs plc has recently issued a consolidated prospectus aimed at investors in the United Kingdom. This valuable document consolidates insights from earlier prospectus editions and offers a detailed guide into the company's shares. The consolidated prospectus serves as a transparent resource for...
Continue Reading
FirstFarms A/S Reports Q1 Challenges Overview of FirstFarms' Financial Performance FirstFarms' financial results for the first quarter reveal unexpected challenges that have significantly influenced its operational landscape. The company faced notably low pig prices at the quarter's onset, accompanied by a disturbing outbreak of foot and mouth disease (FMD) affecting its...
Continue Reading
Shake Shack's Fourth Quarter Performance Shake Shack, Inc. (NYSE: SHAK) has reported a remarkable fourth quarter, demonstrating resilience and notable growth in its financial performance. The company achieved an adjusted earnings per share of 26 cents, surpassing analysts’ expectations, which were set at 24 cents. Sales Growth and Financial Highlights During this...
Continue Reading
